Literature DB >> 12672251

1,3-dioxolane-based ligands as a novel class of alpha1-adrenoceptor antagonists.

Livio Brasili1, Claudia Sorbi, Silvia Franchini, Massimo Manicardi, Piero Angeli, Gabriella Marucci, Amedeo Leonardi, Elena Poggesi.   

Abstract

1,3-Dioxolane-based compounds (2-14) were synthesized, and the pharmacological profiles at alpha(1)-adrenoceptor subtypes were assessed by functional experiments in isolated rat vas deferens (alpha(1A)), spleen (alpha(1B)), and aorta (alpha(1D)). Compound 9, with a pA(2) of 7.53, 7.36, and 8.65 at alpha(1A), alpha(1B), and alpha(1D), respectively, is the most potent antagonist of the series, while compound 10 with a pA(2) of 8.37 at alpha(1D) subtype and selectivity ratios of 162 (alpha(1D)/alpha(1A)) and 324 (alpha(1D)/alpha(1B)) is the most selective. Binding assays in CHO cell membranes expressing human cloned alpha(1)-adrenoceptor subtypes confirm the pharmacological profiles derived from functional experiments, although the selectivity values are somewhat lower. Therefore, it is concluded that 1,3-dioxolane-based ligands are a new class of alpha(1)-adrenoceptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672251     DOI: 10.1021/jm021078o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment.

Authors:  Xin Zhao; Minsheng Chen; Biyun Huang; Hong Ji; Mu Yuan
Journal:  Int J Mol Sci       Date:  2011-10-20       Impact factor: 5.923

2.  Exhaustive CoMFA and CoMSIA analyses around different chemical entities: a ligand-based study exploring the affinity and selectivity profiles of 5-HT1A ligands.

Authors:  Sara Guariento; Silvia Franchini; Michele Tonelli; Paola Fossa; Claudia Sorbi; Elena Cichero; Livio Brasili
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.